Biocytogen Expands Partnership with Merck
Friday, August 26, 2022
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen") and Merck have entered into a global licensing agreement for the use of Biocytogen's RenMice™ platform. This agreement grants Merck full access to Biocytogen's RenMice™ platform for the discovery and development of fully human antibody therapeutics for unlimited drug targets. Merck will assume responsibility for clinical development, manufacturing, and commercialization, while providing Biocytogen with development and regulatory milestone payments. The agreement was reached following an initial evaluation period.
Dr. Yuelei Shen, Founder, Chairman, and CEO of Biocytogen, expressed satisfaction with the agreement, stating that it offers Merck access to one of the most advanced fully human antibody discovery platforms. Biocytogen is pleased that Merck recognized the potential of the RenMice™ platform in expediting antibody development for challenging and novel targets.
